Epigenetic aberrations are now well recognized as very frequent and also as early events in the process of malignant transformation. It is very often reported that gene-specific hypermethylation occurs in the context of global hypomethylation. 1 Accordingly, experimentally induced reduction of global methylation levels increases tumour formation in mice under certain circumstances. 2 Somewhat contradictory, in patients with myelodysplastic syndrome (MDS), the induction of hypomethylation using DNA methyltransferase inhibitors leads to very promising clinical response rates and haematological improvement. 3 Therefore, we analysed the global methylation level in a large cohort of MDS patients comprising all subgroups (n ¼ 127), to figure out the molecular mechanisms underlying this unexpected finding. Results were compared to an age-matched control group of healthy subjects (n ¼ 26; see Table 1 ). All samples were retrieved and processed following the guidelines of the local Ethics Committee.
Mononuclear cells were isolated from bone marrow aspirates and the global DNA methylation level was assessed using two completely independent methods. First, the methylation level of the highly repetitive LINE-1 sequence element, which is scattered throughout the human genome, was measured employing Pyrosequencing technology. The methylation status Letters to the Editor of this highly repetitive element is a good surrogate marker for global methylation level. 4 Second, the incorporation of nucleotides after methylation-sensitive digestion of genomic DNA was determined. The amount of nucleotides incorporated depends on the fraction of restriction enzyme recognition sites blocked by cytosine methylation and is a direct measure of the methylation status of the human genome. 5 In addition, for 12 patient samples and 2 controls, sufficient genomic DNA was available for methylation analysis by Southern blotting with a LINE-1 probe, the gold standard for detection of hypomethylation for many years.
Unexpectedly, the methylation level of the LINE-1 sequences demonstrated a distinct and statistically highly significant increase in global DNA methylation in MDS patients compared with the control group. This hypermethylation correlates highly significantly with the risk score according to the International Prognostic Scoring System (Figure 1a ), the blast count ( Figure 1b ) and the karyotype ('good, intermediate, poor'; Figure 1c ). Measuring nucleotide incorporation after methylation-sensitive restriction digestion, as described above, provided very similar results (data not shown).
An increase in global methylation could already be found in low-risk MDS patients without any sign of an increase in blast count (see Figures 1a and b) . Also, a favourable karyotype was already associated with an increase in global methylation levels in MDS patients (see Figure 1c) . The control group was carefully age-matched, and the different risk groups showed a very similar mean age as well. Therefore, an age-related increase in methylation can be excluded as a confounding factor. Supporting these results, Southern blot analysis of 12 samples provided no evidence at all for a reduction in global DNA methylation level, as would be indicated by the appearance of additional low molecular weight fragments following the digestion with HpaII in MDS samples compared with the controls (data not shown; probe preparation and hybridization conditions for Southern blotting were essentially as described 6 ). As the cytosine methylation level in the whole genome was measured, a moderate increase by 6% (from 65 to 71%; see Figure 1a ) implies an altered chromatin structure of thousands of loci (or millions of base pairs).
In concordance with the literature, the tumour suppressor gene p15
INK4b showed frequent aberrant hypermethylation in Scoring System (a), the blast count (b) and the karyotype (c). The LINE-1 methylation level was measured using the Pyrosequencing methodology, and served as a surrogate marker for the global methylation level of the whole genome. Primers were purchased from Biotage (Uppsala, Sweden) and Pyrosequencing was performed essentially as described. 7 Statistical differences were calculated using the Mann-Whitney U test.
this patient cohort, which correlates with disease progression. p15
INK4b methylation levels were measured quantitatively by high resolution Pyrosequencing (data not shown). 7 These results may provide a molecular explanation for the success in treating MDS patients with hypomethylation-inducing agents and why patients with a poor karyotype respond best (see Griffiths Tyrosine kinase (TK) inhibitors directed against the BCR-ABL TK domain have become the standard of treatment in patients with chronic myeloid leukemia (CML). In a proportion of patients, however, resistance to TK inhibitors may occur, which, in the case of imatinib, has been associated with point mutations within the ABL TK domain in 40-90% of instances, depending on the CML phase, the methodology of detection and the definition of resistance. 1 Mutations conferring resistance frequently occur at the ATP-binding site (P-loop) or at other sites directly affecting drug binding or conformation of the kinase (activation loop, catalytic domain). The level of resistance to individual TK inhibitors may vary from slightly reduced sensitivity to total insensitivity. In patients receiving treatment with imatinib, mutations conferring only moderately impaired sensitivity may be approached by increasing the dose, while the presence of mutations associated with a high level of resistance provides an indication for switching treatment to second generation compounds, such as dasatinib or nilotinib.
2 Point mutations reported to confer high levels of resistance to imatinib include for example, Y253F/H, E255K/V, T315I, or H396P/R. 2 Dasatinib and nilotinib were shown to be instrumental against most of these mutations, 3 but the AA position 315 (-T315I) remains problematic because none of the currently approved TK inhibitors are effective in this instance. 4 Moreover, recent data indicate that a range of specific mutations other than the T315I may occur before and during treatment with dasatinib (V299L, T315A, F317I/S/V, F317L) or nilotinib (Y253H, E255V, F359C). 5 These observations underscore the importance of monitoring patients on treatment with TK inhibitors for the presence of mutations. A number of studies in CML patients report on the occurrence of mutations in the entire BCR-ABL TK domain. Recent studies in patients treated with imatinib indicate that E250K, Y253F, E255K, T315I, M351T and F359V account for 60-70% of all mutations. Mutations located within the P-loop appear to be most frequent and are suggested to correlate with poor outcome. 6 A number of methods have been employed to detect mutant clones including, for example, PCR amplification coupled with direct sequencing of the BCR-ABL TK domain, high-performance liquid chromatography, the SEQUENOM MassARRAY system, or allele-specific oligonucleotide-PCR amplification. These techniques display different detection limits for the identification of mutant clones ranging from 0.01-30%. Detection of a mutation within the ABL TK domain does not necessarily imply impending onset of clinically resistant disease, particularly if the size of a mutant clone is small. 7 Mutant clones have been reported to disappear spontaneously which may, at least in part, be attributable to the occurrence of mutations in cells with restricted proliferative capacity. 8, 9 Qualitative methods for mutational analysis may therefore have limited potential to reliably assess the risk of clinically resistant disease, especially if mutant clones present at very low levels are detected. 8 It is currently a matter of discussion whether the detection of small mutant BCR-ABL clones, for example, below the level of 1%, is clinically useful. The clinical benefit of sensitive techniques for mutational analysis could be increased if the size of mutant clones could be monitored, to facilitate timely detection of clonally expanding mutant cells during treatment.
8 Current approaches to assessing the size of mutant clones include for example, pyrosequencing, 9 SEQUENOM MassARRAY analysis, 10 or the polymerase colony assay.
11 These techniques, however, have limitations with regard to broad application in clinical diagnosis,
